Will I Need Insulin for Type 2 Diabetes? What Decides It, and What Actually Delays the Day It Starts
It is usually the second question after a diagnosis of type 2 diabetes, and often the one people are too uneasy to ask out loud. Does this end with injections.
The honest answer has three parts, and none of them is the one people fear.
💡 The short version.
🔹 Most people with type 2 diabetes never use insulin. Of those who do, it is typically after ten to fifteen years or more, and often longer.
🔹 Some need it for a few weeks and then stop. Insulin started at diagnosis, during an infection, around surgery or in pregnancy is frequently temporary, and coming off it is normal rather than remarkable.
🔹 What you do in the first few years has an outsized effect on the timeline. That is where the real answer to the question lies, and it is the part nobody mentions.
📉 Why type 2 diabetes moves at all
Type 2 diabetes starts with insulin resistance: muscle, liver and fat stop responding properly to insulin, so the pancreas compensates by producing more. For years this works. Blood glucose stays normal while insulin output quietly climbs, and nobody knows anything is happening.
Glucose only starts rising when the compensation begins to fail. Which means something uncomfortable about the moment of diagnosis:
📊 By the time type 2 diabetes is diagnosed, around half of beta-cell function is already gone.
This came out of the large British outcomes study that followed people from diagnosis onward. The glucose rise is the late event, not the first one — the decline had been underway for years before anyone measured anything.
It also explains why the condition tends to need more treatment over time even when nothing has been done wrong. The underlying decline continues. Needing a second tablet after six years is not a failure of discipline, it is the natural history of the disease.
That same decline is what eventually brings insulin into the picture for some people. Once beta cells can no longer produce enough, no drug that works by squeezing more insulin out of them has anything left to squeeze.
⏳ Who ends up using insulin, and when
| Situation | What usually happens |
|---|---|
| Diagnosed with moderately raised glucose, treated early | Oral treatment for many years. A large share of people never move on to insulin at all |
| Long duration, ten to twenty years | Insulin becomes more likely as beta-cell reserve falls. This is the main group |
| Very high glucose at diagnosis, with weight loss and thirst | Insulin often started immediately — and often stopped again once things settle. See below |
| Pregnancy | Insulin is used because most other agents are avoided. Temporary |
| Serious infection, surgery, hospital admission | Short-term insulin while unwell, then back to the usual regimen |
| A course of steroid tablets | Glucose can rise sharply for the duration. Usually temporary |
| Actually has slow-onset type 1 rather than type 2 | Insulin arrives early and permanently — and the diagnosis was wrong. Covered further down |
🔄 Insulin at diagnosis is often temporary
This is the piece almost nobody is told, and it causes a lot of unnecessary distress.
✅ Very high glucose poisons the cells that make insulin — and the damage reverses.
Sustained high blood sugar suppresses beta-cell function directly. The cells are not dead, they are overwhelmed. The term for it is glucotoxicity.
Bringing glucose down quickly with a short course of insulin lifts that suppression, and beta cells frequently recover a meaningful amount of function. Many people started on insulin at diagnosis come off it within weeks or months and continue on tablets alone, sometimes for years.
So being started on insulin at the very beginning says something about how high the number was that week. It says much less about where you will be in two years.
If someone is diagnosed with an HbA1c above about 10% (86 mmol/mol), or is losing weight, passing large volumes of urine and extremely thirsty, starting insulin early is the correct move rather than a gloomy one. Waiting while tablets slowly take effect leaves the glucotoxicity in place.
🧩 Why the words insulin-dependent were dropped
Older material still describes type 1 as insulin-dependent diabetes and type 2 as non-insulin-dependent, often abbreviated IDDM and NIDDM. These labels were formally retired in 1997, and it is worth knowing why, because the confusion they created is still around.
The problem is that they describe the treatment rather than the disease. A person with type 2 diabetes who starts insulin after fifteen years has not become insulin-dependent in any meaningful sense, and has certainly not become type 1. The underlying mechanism has not changed at all. But under the old naming, their label would have had to change, which is incoherent.
| Type 1 | Type 2 | |
|---|---|---|
| Cause | Immune destruction of beta cells | Insulin resistance plus gradual beta-cell decline |
| Insulin produced | Essentially none | Often plenty, especially early — it just does not work well enough |
| Insulin treatment | Required to stay alive, from day one | Sometimes, eventually, and sometimes only briefly |
| Missing a dose | Dangerous within hours — ketoacidosis | Glucose rises, but the acute danger is far lower |
| Onset | Usually fast, often weeks | Usually silent for years before diagnosis |
The practical point for anyone searching this question: using insulin does not reclassify your diabetes. Type 2 treated with insulin is still type 2.
💊 What gets used before insulin, and in what order
Treatment has changed considerably, and the sequence is no longer a simple ladder. What gets added second now depends on what else is going on.
| Step | Usual choice |
|---|---|
| First | Metformin, unless the kidneys do not allow it. Cheap, does not cause hypoglycaemia on its own, does not add weight, and does not push beta cells harder |
| Second, with heart failure or kidney disease | An SGLT2 inhibitor such as dapagliflozin, which is added for those organs rather than only for the glucose |
| Second, with established heart disease or obesity | A GLP-1 receptor agonist, which also reduces weight substantially |
| Second, where cost matters most | A DPP-4 inhibitor such as sitagliptin, pioglitazone, or a sulfonylurea such as glimepiride |
| Later | Insulin, when the combination cannot hold target, or immediately when glucose is very high at diagnosis |
Our guides to choosing and using a single first drug and to combining two or more go through these choices in detail.
⚠️ The drug choice changes the timeline
Here is the part that bears directly on the question, and it was the error in how this subject is usually presented.
📌 Sulfonylureas work by making tired beta cells work harder.
Glimepiride, gliclazide and glipizide lower glucose by stimulating insulin secretion. They are effective, cheap and act quickly. But their effect depends on beta cells that still function, and there is a question about what demanding more output does to cells already in decline.
A long head-to-head trial compared three drugs used alone and measured how many people lost control and needed something added. At five years, failure rates were around 15% on pioglitazone-class treatment, 21% on metformin and 34% on a sulfonylurea. The sulfonylurea worked best in the first year and worst by year five.
Which matters for anyone asking how long they have before insulin: the drug that brings glucose down fastest at the start is not the one that holds it longest.
This is not a reason to stop a sulfonylurea that is working well, and for many people cost and availability settle the question. It is a reason to ask what the plan is, rather than assuming all glucose-lowering tablets are interchangeable.
🎯 What actually delays it
With numbers, because the effect sizes here are larger than most people assume.
- 📈 Good control early pays off for decades. Ten years after the original trial ended, the group that had been tightly controlled at the start still had fewer complications — even though both groups had similar control by then. The phrase for it is the legacy effect, and it means the first years count disproportionately
- ⚖️ Weight loss is the single biggest lever. In a trial of structured weight management, 46% of participants were in remission at one year and 36% at two years — off all diabetes medication with normal HbA1c
- 📏 And it scaled with the weight lost. In those who lost 15 kg or more, remission reached around 86%. Under 5 kg, almost nobody. This is as close to a dose-response curve as lifestyle advice ever gets
- 🚶 Activity improves insulin sensitivity independently of weight, and muscle is where most post-meal glucose is disposed of
- 😴 Sleep below six hours measurably worsens insulin sensitivity within days
- 📅 Not waiting. Leaving an HbA1c above target for a year while hoping it settles spends part of the window when action works best
Remission is worth saying plainly: type 2 diabetes can go into remission, and the main route is substantial weight loss relatively early in the condition. It is not available to everybody, and it is less likely after many years. But it is real, it is measured, and it is not fringe. Our guide to weight loss and what the evidence supports covers the methods, and prediabetes and reversing it covers the stage before.
🧬 Are you certain it is type 2?
Two conditions get labelled type 2 and are not, and both change the answer to the insulin question completely.
🔬 LADA — latent autoimmune diabetes in adults.
This is type 1 arriving slowly in an adult. The same immune destruction of beta cells, but over years instead of weeks, so it looks like type 2 at first and is treated as such. Estimates suggest it accounts for somewhere between 2% and 12% of adults diagnosed with type 2.
Worth questioning the diagnosis if: you are lean rather than carrying extra weight; there is no family history of type 2 diabetes; tablets stopped working unusually quickly, within a year or two; or there is another autoimmune condition such as thyroid disease or coeliac disease.
It is settled with two blood tests — GAD antibodies and C-peptide, which measures how much insulin the pancreas is actually making. Getting this right matters, because insulin is needed early and the sulfonylureas will not hold.
MODY is the other one. A single inherited gene fault, usually appearing before age twenty-five, with diabetes in a parent and often a grandparent, in someone who is not overweight and has no insulin resistance. It matters because some forms respond dramatically to low-dose sulfonylureas and need no insulin at all — people have been taken off lifelong insulin injections after the correct diagnosis. Rare, but worth raising where the pattern fits.
😰 The fear itself is worth naming
Reluctance to start insulin is common enough to have a name in the literature: psychological insulin resistance. The usual reasons are consistent — it feels like personal failure, like the disease has won, like the needles will dominate daily life, like it signals the end stage.
None of these survives contact with the facts.
- 🎯 It is not a punishment for poor control. Beta-cell decline continues in people who do everything right. Duration is a bigger predictor than behaviour
- 💉 Modern needles are very fine and very short. Most people report the injection itself is less uncomfortable than the fingerprick test they have been doing for years
- 🕒 A basal regimen is one injection a day, usually at the same time each evening. Not an hourly intrusion
- ⚠️ Delaying has a price. Every year spent above target with no change accumulates damage to eyes, kidneys and nerves that does not reverse. This is the actual risk, and it is larger than the risk of starting
- 🔄 It is not always permanent, as above
Where nerve symptoms have already begun, our guide to diabetic neuropathy covers what can and cannot be reversed — and that section is the clearest argument against waiting.
🩸 Which treatments can drop your sugar too low
A practical distinction that affects how much monitoring is needed, and one people are rarely given clearly.
| Treatment | Hypoglycaemia risk alone |
|---|---|
| Metformin | Essentially none. It does not force insulin release |
| DPP-4 inhibitors (sitagliptin) | Very low — they work in a glucose-dependent way |
| SGLT2 inhibitors (dapagliflozin) | Very low, since they remove glucose through the urine |
| Pioglitazone | Very low |
| Sulfonylureas (glimepiride) | Real, and the main one among tablets. Higher with skipped meals, alcohol, kidney impairment and in older people |
| Insulin | Real, and dose-related. The reason doses are built up slowly |
Combining a sulfonylurea or insulin with anything else raises the risk of the pair, which is why a sulfonylurea dose is often cut when insulin is introduced rather than both being run at full strength.
📞 When to seek help
🚨 Urgent: vomiting with high glucose, deep or rapid breathing, a fruity smell on the breath, abdominal pain or drowsiness — these can indicate ketoacidosis, which does occur in type 2 diabetes and can occur at near-normal glucose in anyone taking an SGLT2 inhibitor. Also urgent: a hypoglycaemic episode needing someone else to help you, confusion, seizures, or sudden change in vision.
Book an appointment if:
- HbA1c has been above target for more than three to six months with no change to treatment
- Glucose is rising despite taking everything as prescribed, which usually means the regimen needs adding to rather than you needing to try harder
- You are lean, have no family history, and tablets stopped working within a year or two — ask about GAD antibodies and C-peptide
- Diabetes diagnosed before twenty-five with a strong family pattern and no excess weight — ask about MODY
- Insulin has been suggested and you have been putting it off. Say so directly; the reasons are common and there are usually options to discuss
- Low glucose episodes on a sulfonylurea, particularly if meals are irregular
- A course of steroid tablets is starting, since glucose will usually rise and the plan should be set in advance
- Pregnancy or planning one, since the medication list changes
- Numbness, tingling or burning in the feet, or any foot ulcer or wound that is not healing
- Eye or kidney screening has lapsed, both of which are silent until late
- You are interested in trying for remission, which works best when started early and is worth raising rather than waiting to be offered
❓ Frequently asked questions
Will everyone with type 2 diabetes eventually need insulin?
No. Most people never do. Among those who do, it is usually after ten to fifteen years or more, and for some it is temporary rather than permanent.
Does starting insulin mean my type 2 diabetes became type 1?
No. The underlying mechanism does not change. Type 2 diabetes treated with insulin is still type 2. The old labels insulin-dependent and non-insulin-dependent were retired in 1997 for exactly this reason.
Can you come off insulin once you have started?
Often, yes. Insulin started at diagnosis for very high glucose, or during infection, surgery or pregnancy, is frequently stopped once things settle and tablets resume.
Why was I put on insulin straight away at diagnosis?
Very high glucose suppresses the cells that make insulin, a state called glucotoxicity. Bringing it down fast lifts that suppression and beta-cell function often recovers, so the insulin is commonly short-term.
Why do my tablets stop working after a few years?
Beta-cell function declines gradually in type 2 diabetes, and roughly half of it is already lost at diagnosis. Needing a second drug later reflects the natural course, not a failure of effort.
Do sulfonylureas wear out the pancreas?
They work by stimulating insulin secretion, and lose effect faster than other options. In a five-year comparison, about 34% lost control on a sulfonylurea against 21% on metformin.
Can type 2 diabetes go into remission?
Yes. In a structured weight management trial, 46% were in remission at one year and 36% at two years. In those losing 15 kg or more it reached around 86%.
What is LADA and how do I know if I have it?
Slow-onset type 1 diabetes in adults, often misread as type 2. Suspect it if you are lean, have no family history, or tablets failed within a year or two. GAD antibodies and C-peptide settle it.
Which diabetes tablets can cause low blood sugar?
Mainly sulfonylureas such as glimepiride. Metformin, DPP-4 inhibitors, SGLT2 inhibitors and pioglitazone carry very little risk when taken on their own.
Does delaying insulin cause harm?
Yes. Time spent above target accumulates damage to eyes, kidneys and nerves that does not reverse. The risk of waiting is generally larger than the risk of starting.
📑 Sources and editorial
- United Kingdom Prospective Diabetes Study findings on beta-cell function at the time of type 2 diabetes diagnosis and its continued decline on treatment
- Ten-year post-trial follow-up of the United Kingdom Prospective Diabetes Study demonstrating persistent reduction in complications from early intensive glycaemic control, the legacy effect
- A Diabetes Outcome Progression Trial comparing monotherapy durability of rosiglitazone, metformin and glyburide, with cumulative incidence of monotherapy failure at five years
- 1997 report of the expert committee on the diagnosis and classification of diabetes mellitus, which replaced the terms insulin-dependent and non-insulin-dependent diabetes with type 1 and type 2
- Evidence on glucotoxicity and reversible suppression of beta-cell function, and on short-term intensive insulin therapy at diagnosis of type 2 diabetes with subsequent discontinuation and durable glycaemic remission in a proportion of patients
- Current consensus guidance on the pharmacological management of hyperglycaemia in type 2 diabetes, including metformin as initial therapy and the selection of second-line agents according to atherosclerotic cardiovascular disease, heart failure, chronic kidney disease and weight
- Guidance on individualised glycated haemoglobin targets, including relaxation of targets in older or frail adults and where hypoglycaemia risk is significant
- Diabetes Remission Clinical Trial outcomes at one and two years, including remission rates overall and stratified by magnitude of weight loss
- Literature on latent autoimmune diabetes in adults, including reported prevalence among adults diagnosed with type 2 diabetes, clinical features suggesting the diagnosis, and the role of glutamic acid decarboxylase antibody and C-peptide testing
- Literature on maturity-onset diabetes of the young, including inheritance pattern, clinical features, and response of specific subtypes to low-dose sulfonylurea therapy allowing withdrawal of insulin
- Comparative hypoglycaemia risk across glucose-lowering drug classes, including the glucose-dependent mechanism of dipeptidyl peptidase-4 inhibitors and the insulin-independent action of sodium-glucose co-transporter-2 inhibitors
- Guidance on euglycaemic diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors, and on ketoacidosis occurring in type 2 diabetes
- Guidance on management of hyperglycaemia during systemic corticosteroid therapy, intercurrent illness, surgery and pregnancy in type 2 diabetes
- Literature on psychological insulin resistance, including reported patient reasons for declining insulin initiation and the clinical consequences of delayed treatment intensification
- Related reading: choosing a first diabetes drug, combining diabetes medicines, prediabetes and reversing it, when metabolic control slips, diabetic neuropathy, weight loss and the evidence
- Related products: Glucophage (Metformin), Januvia (Sitagliptin), Dapavel (Dapagliflozin), Actos (Pioglitazone), Amaryl (Glimepiride), diabetes category
- RXshop Editorial Team — reviewed by Daniel Kim, MD — Endocrinologist & Diabetes Specialist
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.